Antabio's MEM-ANT3310 Completes Phase 1 Trial, Showing Promise Against Multidrug-Resistant Infections
核心洞察
Antabio's MEM-ANT3310, a novel antibacterial combination, has successfully completed its Phase 1 clinical trial in healthy volunteers, demonstrating good tolerability.
The trial assessed the safety, tolerability, and pharmacokinetics of ANT3310, a serine-beta-lactamase (搜索) inhibitor, both alone and in combination with meropenem.
Results indicate that ANT3310 was well-tolerated with no serious adverse events and exhibited compatible pharmacokinetics with meropenem, supporting further patient studies.
Antabio, a biopharmaceutical company focused on developing antibacterial treatments, has announced the completion of a Phase 1 clinical trial for MEM-ANT3310 in healthy volunteers. This next-generation broad-spectrum antibacterial combination is designed to address the increasing challenge of antimicrobial resistance in severe hospital infections. The trial's positive results support further patient studies of MEM-ANT3310.
Addressing Antimicrobial Resistance
MEM-ANT3310 combines meropenem (MEM), a carbapenem, with ANT3310, a novel serine-beta-lactamase (搜索) (SBL) inhibitor. This combination provides coverage against priority Gram-negative pathogens, including OXA-carbapenem-resistant Acinetobacter baumannii (搜索) (CRAB), KPC- and OXA-carbapenem-resistant Enterobacterales (搜索) (CRE), and Pseudomonas aeruginosa (搜索) (PA). These pathogens pose a significant threat in hospital settings due to their resistance to multiple antibiotics.
Phase 1 Trial Details
The Phase 1 trial included 72 healthy volunteers and evaluated the safety, tolerability, and pharmacokinetic (PK) profile of single and multiple ascending doses (SAD/MAD) of intravenous ANT3310 administered alone. The study also investigated the potential PK interaction between ANT3310 and meropenem, followed by an assessment of the MEM-ANT3310 combination during multiple intravenous dosing.
Key Findings
ANT3310 was well-tolerated at all doses, with no serious adverse events, dose-limiting toxicities, or clinically relevant abnormalities reported. The PK parameters of ANT3310 were consistent with those observed in preclinical studies, showing dose-dependent increases in exposure. Importantly, ANT3310 and meropenem demonstrated compatible PK profiles with no mutual PK interaction.
Future Directions
"With matching PK and good tolerability, MEM-ANT3310 shows great promise to address serious infections whenever multidrug resistance is a concern in hospitalised patients," said Marc Lemonnier, CEO of Antabio. "With a uniquely broad coverage, we believe MEM-ANT3310 will be very well positioned to meet the urgent medical needs in high-risk patients, especially when multidrug-resistant pathogens or polymicrobial infections are suspected."
Antabio is currently conducting a Phase 1 PK study of MEM-ANT3310 in subjects with impaired renal function and is planning a second PK study to assess the distribution of MEM-ANT3310 in the lung (epithelial lining fluid) in healthy volunteers. These studies will further inform the development of MEM-ANT3310 as a potential treatment for severe hospital infections.